Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aguracingene cadoparvovec - MeiraGTx

Next Previous
Drug Profile

Aguracingene cadoparvovec - MeiraGTx

Alternative Names: A-003 - MeiraGTx; AAV-CNGA3; AAV2/8-hG1.7p.coCNGA3; CNGA3-gene-therapy-AGTC; Recombinant-adeno-associated-virus-vector-expressing-GNGA

Latest Information Update: 26 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCL Business
  • Developer MeiraGTx
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colour vision defects
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colour vision defects

Most Recent Events

  • 11 Jun 2025 Discontinued - Phase-I/II for Colour vision defects (In adolescents, In children, In adults) in United Kingdom (Intraocular) prior to June 2025
  • 11 Jun 2025 Discontinued - Phase-I/II for Colour vision defects (In adolescents, In children, In adults) in USA (Intraocular) prior to June 2025
  • 04 Apr 2024 MeiraGTx terminates a long term follow-up phase I/II trial in Colour vision defects (In adolescents, In adults, In children) in USA and United Kingdom (Intraocular, Injection) due to strategic decision to not further develop AAV8-hCARp.hCNGB3 and AAV8-hG1.7p.coCNGA3. The decision is not due to safety concerns (NCT03278873) (EudraCT2016-003856-59)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top